Extracts of Salacia species from roots, stems, and leaves have been used for the treatment of diabetes and other associated risk factors in Asia. Studies indicate that Salacia extracts modulate multiple targets that influence carbohydrate and lipid metabolism. This study is to examine the effect of differing doses of a novel form of Salacia extract (SE) on glucose and insulin response to an oral sucrose load in healthy individuals (South Asian Population). Thirty five (N=35, 18 to 55 years of age; BMI ≥24.50 to 29.50 Kg/m2) adult healthy individuals (male and female)were randomly assigned to ingest SE at dosages of 200 mg SE, 300 mg SE and 500 mg (OmniLeanTM) or placebo (PLA) in a single center, double‐blind, randomized, placebo controlled parallel design. Plasma glucose and plasma insulin responses were measured after 0, 30, 60, 90, 120, 180 min of ingesting oral sucrose standard solution and Area under curve for glucose (AUCglucose) and insulin response (AUCinsulin) was calculated. ANOVA and paired t‐tests were used to examine differences between treatments and over baseline. Compared with PLA, SE 500 mg significantly lowered blood sugars and insulin from 60 minutes, 90 minutes and 120 minutes, SE 300 mg significantly lower at 90 min and 180 min and 200 mg at 90 min and 120 minutes. AUCglucose was not significant. Plasma insulin levels and AUCinsulin were significantly lowered after ingestion of SE. No significant adverse events were observed at any dose. Thus, in reducing the early rise in blood glucose and insulin after sucrose ingestion, Salacia extract (SE) prevents the occurrence of reactive hypoglycemia; the present study confirm that this nutritional ingredient may be of value in reducing post prandial insulin and glucose.Support or Funding InformationOmniActive Health Technologies Ltd., Mumbai, India